Research

Hormonal

Pioglitazone treatment decreases COL6A3 mRNA expression in obese patients with type 2 diabetes, with the magnitude of decrease proportional to baseline expression levels.

For individuals with type 2 diabetes, the medication pioglitazone has been shown to reduce markers of fat tissue fibrosis (COL6A3). This reduction is most pronounced in those with higher baseline levels. This suggests that pioglitazone may help remodel adipose tissue, potentially reducing inflammation. This is a prescription medication and should be discussed with a healthcare provider.

GoodSupportsMEDIUM confidence
Pioglitazone decreased COL6A3 mRNA, and the change was inversely proportional to baseline COL6A3 mRNA (r = -0.95, P < 0.0001).
Magdalena Pasarica et al. · The Journal of Clinical Endocrinology & Metabolism · 2009

Why this rating

Small sample size (n=14) for the pioglitazone study limits generalizability, but the statistical correlation is very strong.

Source

Adipose Tissue Collagen VI in Obesity

Magdalena Pasarica et al. · The Journal of Clinical Endocrinology & Metabolism · 2009

DOI 10.1210/jc.2009-0947

cross_sectional · n=132Cited 332×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →